{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:45:18Z","timestamp":1783637118179,"version":"3.55.0"},"reference-count":87,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1002\/jcph.1736","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T04:56:32Z","timestamp":1607057792000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Pharmacology at the Intersection of Women's Health and Regulation: Drug Development Considerations for Uterine Fibroids"],"prefix":"10.1002","volume":"60","author":[{"given":"Jihong","family":"Shon","sequence":"first","affiliation":[{"name":"Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zou","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doanh","family":"Tran","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley K.","family":"Seo","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Lu","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research U.S. Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/656571"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.14640"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2015.11.016"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S138982"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmw023"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.5787"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt058"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jog.14002"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1933719114533728"},{"key":"e_1_2_11_11_1","unstructured":"U.S. FDA Leupron Depot\u00aeprescribing information.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019943s034lbl.pdf. Accessed July 2020."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2018.1417381"},{"key":"e_1_2_11_13_1","unstructured":"U.S. FDA Oriahnn\u00aeprescribing information.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213388s000lbl.pdf. Accessed July 2020."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2014.06.041"},{"key":"e_1_2_11_15_1","unstructured":"European Medicines Agency Summary of product characteristics of Esmya\u00ae.www.medicines.org.uk\/emc\/product\/3951\/smpc. Accessed July 2020."},{"key":"e_1_2_11_16_1","unstructured":"Health Canada product monograph of Fibristal\u00ae.www.fibristal.ca\/docs\/Fibristal_Product_Monograph_E.pdf. Accessed July 2020."},{"key":"e_1_2_11_17_1","unstructured":"European Medicines Agency \u2010 Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk (March 13 2020).https:\/\/www.ema.europa.eu\/en\/news\/suspension-ulipristal-acetate-uterine-fibroids-during-ongoing-ema-review-liver-injury-risk. Accessed July 2020."},{"key":"e_1_2_11_18_1","unstructured":"Health Canada Safety review finds possible link between Fibristal and risk of liver injury.www.healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2019\/68806a-eng.php. Accessed July 2020."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2017.09.004"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.02.064"},{"issue":"2","key":"e_1_2_11_21_1","first-page":"CD000547","article-title":"Pre\u2010operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids","author":"Lethaby A","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_22_1","unstructured":"U.S. FDA Orilissa\u00aeprescribing information.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210450s002lbl.pdf. Accessed July 2020."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmu048"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)61020-8"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000158742.11877.99"},{"issue":"5","key":"e_1_2_11_26_1","first-page":"290","article-title":"Associations among sex hormone binding globulin concentrations and characteristics of the metabolic syndrome in obese women","volume":"17","author":"Cikim AS","year":"2004","journal-title":"Diabetes Nutr Metab"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1505606"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/11318100-000000000-00000"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1710-5"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1510311"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S133212"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2013.4334"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2013.08.008"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.08.037"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2014.02.008"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103182"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103180"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/1745505717692591"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.06.012"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002462"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP38053"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/10601333.2015.1064131"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.07.013"},{"key":"e_1_2_11_44_1","unstructured":"U.S. Food and Drug Administration Guidance for Industry Drug\u2010Induced Liver Injury: Premarketing Clinical Evaluation.2009.https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-induced-liver-injury-premarketing-clinical-evaluation. Accessed August 26 2020."},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1506766"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.03.092"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00388-8"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(00)00195-1"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.06.044"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1550070"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00960-1"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200302000-00009"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31818aa930"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1159\/000028193"},{"issue":"10","key":"e_1_2_11_55_1","first-page":"1119","article-title":"Cytochrome P4503A4\u2010mediated N\u2010demethylation of the antiprogestins lilopristone and onapristone","volume":"25","author":"Jang GR","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9304-7"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/1933719114549850"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602532.2011.605791"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0607-4"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201800487"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.10.033"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.018"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0977-4"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.12.206"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01875"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-6483(11)60210-1"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1076791"},{"issue":"12","key":"e_1_2_11_68_1","first-page":"2785","article-title":"A prospective, randomized, pharmacodynamic study of quick\u2010starting a desogestrel progestin\u2010only pill following ulipristal acetate for emergency contraception","volume":"30","author":"Brache V","year":"2015","journal-title":"Hum Reprod"},{"key":"e_1_2_11_69_1","unstructured":"US FDA ella\u00aePrescribing information.www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022474s000lbl.pdf. Accessed August 26 2020. Accessed July 2020."},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14443"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-1208.142476"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1085510"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0044"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000964"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002933"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb05525.x"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.439"},{"issue":"4","key":"e_1_2_11_78_1","first-page":"263","article-title":"Role of goserelin\u2010depot in the clinical management of uterine fibroids","volume":"21","author":"Cagnacci A","year":"1994","journal-title":"Clin Exp Obstet Gynecol"},{"key":"e_1_2_11_79_1","unstructured":"Efficacy and safety of OBE2109 in subjects with heavy menstrual bleeding associated with uterine fibroids (PRIMROSE 1) NCT03070899.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03070899. Accessed August 26 2020."},{"key":"e_1_2_11_80_1","unstructured":"Efficacy & safety study of relugolix in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 2) NCT03103087.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03103087. Accessed August 26 2020."},{"key":"e_1_2_11_81_1","unstructured":"A randomized parallel\u2010group double\u2010blind and placebo\u2010controlled multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids ClinicalTrials.gov Identifier: NCT03400956.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03400956. Accessed August 26 2020."},{"key":"e_1_2_11_82_1","unstructured":"Assess safety and efficacy of vilaprisan in subjects with uterine fibroids (ASTEROID 6) ClinicalTrials.gov Identifier: NCT03194646.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03194646. Accessed August 26 2020."},{"key":"e_1_2_11_83_1","unstructured":"Assessment of safety and efficacy of vilaprisan in subjects with uterine fibroids (ASTEROID 7) ClinicalTrials.gov Identifier: NCT03699176.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03699176. Accessed August 26 2020."},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2013.08.039"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S147318"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(00)00195-1"},{"key":"e_1_2_11_87_1","first-page":"CD005287","article-title":"Selective estrogen receptor modulators (SERMs) for uterine leiomyomas","volume":"10","author":"Deng L","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_88_1","first-page":"CD009505","article-title":"Aromatase inhibitors for uterine fibroids","volume":"10","author":"Song H","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1736","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.1736","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T17:00:58Z","timestamp":1693760458000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":87,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/jcph.1736"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1736","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"2020-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}